Understanding Key Issues in the Treatment of Castrate-Resistant Prostate Cancer
Source: Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Module

David I. Quinn, MD, PhD, explores current approaches for managing patients with castrate-resistant prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Define the criteria by which a patient is classified as castrate resistant
  • Describe current treatment approaches for patients with castrate-resistant prostate cancer
  • Explain factors to consider when choosing treatment options for castrate-resistant prostate cancer patients
  • Cite novel research advances and therapeutic treatment options for the treatment of patients with castrate-resistant prostate cancer

Topics covered include:

  • Introduction
  • Definition of CRPC, Androgen-Independent Prostate Cancer, and Hormone-Refractory Prostate Cancer
  • Influence of Metastatic Site on Treatment Course
  • Optimal Androgen-Deprivation Therapy
  • Value of Secondary Hormone Therapy: Who Are the Ideal Candidates?
  • Current Treatment Approaches for CRPC
  • Therapeutic Alternatives Following Docetaxel Failure
  • Factors Influencing Choice of Treatment
  • Nomograms for the Treatment of CRPC
  • Future Strategies and Clinical Trial Data for CRPC
  • Future Treatment Approaches for CRPC: Bone Targeting Strategies
  • Immunotherapy for CRPC
 

Program Directors

  • David I. Quinn
    MD, PhD
    Nicholas J. Vogelzang
    MD

Faculty

  • David I. Quinn
    MD, PhD

Credit Information

  • Release Date:
    February 20, 2009
  • Expiration Date:
    February 19, 2010
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits
  • Adding Radium-223 to Our Current Treatment Paradigm for Metastatic CRPC: My Thoughts

    David I. Quinn MD, PhD - 5/22/2013    6 comments / Last Comment: 8/29/2013
    Radium-223 extended survival in CRPC with minimal toxicity in the ALSYMPCA randomized phase III trial. So when and how should this new therapeutic agent be used in our practices?
  • Bladder Cancer: Are Changes in Chemotherapy Warranted?

    Derek Raghavan MD, PhD, FACP - 4/26/2013    6 comments / Last Comment: 8/20/2013
    The NCCN recently updated its guidelines for the use of chemotherapy in patients with bladder cancer. In this ClinicalThought, I explore which of these changes should definitely be applied in clinical practice and which I believe have only limited evidence to support them.
  • Do We Really Need Chemotherapy Anymore in Prostate Cancer?

    David I. Quinn MD, PhD - 11/30/2012    3 comments / Last Comment: 6/16/2013
    Chemotherapy is not dead in metastatic CRPC, but we may need to re-learn how to optimally use it.
  • CRPC in the Post-Docetaxel Setting: Where Are We Now?

    David I. Quinn MD, PhD - 12/6/2012    6 comments / Last Comment: 7/21/2013
    We can now choose among multiple available agents with level 1 evidence for a survival benefit in patients with mCRPC who progressed with docetaxel. Here’s how I manage my patients with all these choices.
  • Why I Don’t Routinely Screen Asymptomatic White Males for Prostate Cancer

    Derek Raghavan MD, PhD, FACP - 7/29/2013    11 comments / Last Comment: 8/23/2013
    Align your practice with evolving guidelines to avoid unnecessary testing of your patients with prostate cancer